MSKCC's Kravis Center for Molecular Oncology is bringing precision medicine
to every cancer patient as MSKCC. Led by physician-scientist David Solit, the Kravis Center has a simple goal: to define the molecular drivers of disease in all cancer patients. To help with this end, MSKCC uses its signature MSK-IMPACT assay to profile the genetic mutations in a given patient's tumor. This genomic data is then analyzed and made available to MSKCC clinicians right in the patient's chart. With this new, genetic insight, patients whose tumors have a rational molecular target can be either appropriately treated with standard of care therapy or rationally enrolled in an appropriate clinical trial. Moreover, all the de-identified genomic data is aggregated and made available to every MSKCC researcher, which has already led to a number of research publications. This aggregated data is housed and shared through the cBioPortal for cancer genomics, which currently has data for over 30k tumors from almost 28k patients. As it stands, cBioPortal is one of the largest clinical genomic data sets in the world. Through MSKCC's Kravis Center for Molecular Oncology, David Solit and his colleagues are paving the way for precision medicine in both the clinic and the lab.

---

Future of Care NYC is an accessible, New York City-based health tech community. We create a space for both new and established health tech and scientific innovator to create change in healthcare.

Join the Future of Care NYC community: [ Ссылка ]

Follow Future of Care NYC on Instagram: [ Ссылка ]
Like Future of Care NYC on Facebook: [ Ссылка ]
Follow Future of Care NYC on Twitter: [ Ссылка ]

Subscribe to our channel: [ Ссылка ]

свернуть